Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORLESTRIN 21 1/50 vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (LH, FSH). Enhances cervical mucus viscosity, reducing sperm penetration. Thins endometrium, decreasing implantation likelihood.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet (1 mg norethindrone acetate/50 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off therapy.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Norethindrone terminal half-life: 5-14 hours; ethinyl estradiol terminal half-life: 10-20 hours. Clinical context: steady-state reached within 5-7 days, clinically significant for missed dose management.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Norethindrone: primarily hepatic via reduction and conjugation; also CYP3A4-mediated hydroxylation. Ethinyl estradiol: hepatic via CYP3A4, also undergoes sulfation and glucuronidation; enterohepatic recirculation.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Norethindrone: renal (33% as metabolites), fecal (50%); ethinyl estradiol: renal (40% as glucuronide conjugates), fecal (60%)
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Norethindrone: 61% bound to albumin, 36% bound to SHBG; ethinyl estradiol: >97% bound to albumin.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Norethindrone: 4.3 L/kg; ethinyl estradiol: 2.8-4.5 L/kg. Clinical meaning: extensive distribution into tissues, including breast and reproductive organs.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: norethindrone ~64% (first-pass metabolism), ethinyl estradiol ~45% (first-pass metabolism); transdermal and vaginal routes have higher bioavailability.
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dose adjustment required for GFR ≥30 m L/min; avoid use in patients with GFR <30 m L/min due to potential fluid retention and hypertension.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in Child-Pugh class B or C; use with caution in Child-Pugh class A with monitoring for adverse effects.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not indicated for use before menarche; dosing based on adult regimen for postmenarchal adolescents.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not indicated for postmenopausal women; avoid use in elderly due to increased risk of thrombotic events.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases risk of serious cardiovascular events (e.g., stroke, myocardial infarction) from COC use. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women >35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders (DVT, PE), stroke, MI. Hepatic neoplasia. Cigarette smoking. Hypertension. Gallbladder disease. Carbohydrate/lipid metabolism effects. Headache/migraine. Unscheduled bleeding. Depression. Ocular lesions (retinal thrombosis). Hepatic impairment. Pregnancy (must be ruled out before initiation). Lactation: may reduce milk production.
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Hypersensitivity to any component. Thromboembolic disorders (current/history). Cerebrovascular or coronary artery disease. Known or suspected breast carcinoma. Endometrial carcinoma or other estrogen-dependent neoplasia. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy/jaundice with prior pill use. Hepatic adenoma/carcinoma. Known or suspected pregnancy. Active liver disease with abnormal function. Heavy smoking (>15 cigarettes/day) in women ≥35.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No significant food interactions. Grapefruit juice may slightly increase estrogen levels; avoid excessive consumption. No specific dietary restrictions. Take with or without food.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
FDA Pregnancy Category X. Combination hormonal contraceptives (estrogen-progestin) are contraindicated during pregnancy due to association with fetal harm, including cardiovascular defects and limb reduction defects with first-trimester exposure. No increased risk of major malformations reported from inadvertent exposure in early pregnancy, but use is not indicated. Second and third trimester exposure may increase risk of neonatal jaundice and hepatic adenoma in the mother.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk (M/P ratio not established; estimated <1% of maternal dose). May reduce milk production and quality, especially with high doses. Use during breastfeeding is generally not recommended; alternative contraception advised for nursing mothers.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
No dose adjustment applicable because use is contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism) would alter drug levels, but no clinical indication for dosing.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
NORLESTRIN 21 1/50 (norethindrone 1 mg, ethinyl estradiol 50 mcg) is a high-dose combined oral contraceptive. Due to higher estrogen content, it carries increased risk of venous thromboembolism, especially in smokers over 35. Counsel about skipping inactive pills to avoid withdrawal bleed if extended cycle needed. Monitor for breakthrough bleeding and counsel about missed pill management: if one active pill missed, take as soon as remembered, and use backup contraception for 7 days.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one active pill daily at the same time for 21 days, then 7 days off. Withdrawal bleed usually occurs during off week.,If you miss a pill, take it as soon as you remember, even if it means taking two in one day. Use backup contraception (condoms) for the next 7 days.,Do not smoke while taking this medication, especially if over 35, due to increased risk of blood clots.,Contact your healthcare provider immediately if you experience signs of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,This medication does not protect against sexually transmitted infections (STIs). Use condoms for STI prevention.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORLESTRIN 21 1/50 vs ALTAVERA, answered by our medical review team.
NORLESTRIN 21 1/50 is a Oral Contraceptive that works by Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (LH, FSH). Enhances cervical mucus viscosity, reducing sperm penetration. Thins endometrium, decreasing implantation likelihood.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORLESTRIN 21 1/50 and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORLESTRIN 21 1/50 is: One tablet (1 mg norethindrone acetate/50 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off therapy.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORLESTRIN 21 1/50 and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORLESTRIN 21 1/50 is classified as Category C. FDA Pregnancy Category X. Combination hormonal contraceptives (estrogen-progestin) are contraindicated during pregnancy due to association with fetal harm, including cardiovascular. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.